Metastatic squamous cell non-small-cell lung cancer (NSCLC): Disrupting the drug treatment paradigm with immunotherapies

Drugs in Context

Volumn 4, Issue , 2015, Pages

  Scarpace, Sarah L ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Urologic Oncology Service   (United States)

Author keywords

Antibodies; Avelumab; Bevacizumab; Carboplatin; Carcinoma; Cisplatin; Gemcitabine; Immunotherapy; MEDI4736; Molecular targeted therapy; Monoclonal; MPDL3280A; MSB0010718C; Nivolumab; Non small cell lung cancer; Pembrolizumab; Pemetrexed; Programmed cell death 1 receptor; Ramucirumab; Squamous cell

Indexed keywords

DOCETAXEL; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 84958202246     PISSN: 17451981     EISSN: 17404398     Source Type: Journal    
DOI: 10.7573/dic.212289     Document Type: Review

References (25)

1. National Cancer Institute. SEER stat fact sheets: lung and bronchus cancer [cited 2015 Sep 12]. Available from: http://seer.cancer.gov/statfacts/html/lungb.html
2. World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. Lung Cancer [cited 2015 Sep 12]. Available from: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
3. American Cancer Society. Lung Cancer (Non-Small Cell) [cited 2015 Sep 12]. Available from: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-smallcell-lung-cancer
4. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012;18(4):1167-76. http://dx.doi.org/10.1158/1078-0432.CCR-11-2109
5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev Cancer. 2012;12:252-64. http://dx.doi.org/10.1038/nrc3239
6. Tumeh PH, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-71. http://dx.doi.org/10.1038/nature13954
7. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-35. http://dx.doi.org/10.1056/NEJMoa1504627
8. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257-65. http://dx.doi.org/10.1016/S1470-2045(15)70054-9
9. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-28. http://dx.doi.org/10.1056/NEJMoa1501824
10. Henning Schmidt L, Kummel A, Gorlich D, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One. 2015;10(8):e0136023. http://dx.doi.org/10.1371/journal.pone.0136023
11. Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung, and genitourinary cancers. PLoS One. 2015;10(6):e0130142. http://dx.doi.org/10.1371/journal.pone.0130142
12. Food and Drug Administration. Drugs@FDA: Platinol. Label and approval history [cited 2015 Sep 13]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label-ApprovalHistory#apphist
13. de Castria TB, da Silva EM, Gois AF, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2013;8:CD009256. http://dx.doi.org/10.1002/14651858.CD009256.pub2
14. Fossella F, Pereira JF, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21(16):3016-24. http://dx.doi.org/10.1200/JCO.2003.12.046
15. Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005;16:1069-75. http://dx.doi.org/10.1093/annonc/mdi216
16. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-51.
17. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicenter, double-blind, randomised phase 3 trial. Lancet. 2014;384:665-73. http://dx.doi.org/10.1016/S0140-6736(14)60845-X
18. National Comprehensive Network. Clinical Practice Guidelines in Oncology: Non-small cell Lung Cancer. V.7.2015 [cited 2015 Sep 13]. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#nscl
19. D'Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112:95-102.
20. National Institutes of Health. Clinicaltrials.gov. NCI clinical trial number: NCT02041533 [cited 2015 Sep 15]. Available from: https://clinicaltrials.gov/show/NCT02041533
21. National Institutes of Health. Clinicaltrials.gov. NCI clinical trial number: NCT02220894 [cited 2015 Sep 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02220894?term=pembrolizumab+and+lung&rank=9
22. National Institutes of Health. Clinicaltrials.gov. NCI clinical trial number: NCT02142738 [cited 2015 Sep 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02142738?term=pembrolizumab+and+lung&rank=10
23. National Institutes of Health. Clinicaltrials.gov. NCI clinical trial number: NCT02477826 [cited 2015 Sep 15]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02477826?term=nivolumab+and+lung&rank=4
24. National Institutes of Health. Clinicaltrials.gov. NCI clinical trial number NCT02039674 [cited 2015 Sep 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02039674?term=pembrolizumab+and+lung&rank=13
25. National Institutes of Health. Clinicaltrials.gov [cited 2015 Sep 15]. Available from: https://clinicaltrials.gov/ct2/results?term=PD-L1+and+lung&Search=Search